Immunovant Q2 2026 Results: Net Loss of $97.2M, Loss Narrows
Immunovant reported a net loss of $97.2 million for the quarter ended September 30, 2026, compared to $126.5 million in the prior year period. The company maintained a strong liquidity position with $722.3 million in cash and cash equivalents, while research and development expenses remained the primary driver of operating costs at $85.0 million for the quarter.
- Key figure
- Net loss $97.2M